EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF
Metrics: PDF 813 views | HTML 661 views | ?
Farah Khayati1,2,3, Laura Pérez-Cano4, Kamel Maouche5, Aurélie Sadoux1,3, Zineb Boutalbi1,3, Marie-Pierre Podgorniak1,3, Uwe Maskos5, Niclas Setterblad2,6, Anne Janin2,7, Fabien Calvo1,2,3, Céleste Lebbé2,8, Suzanne Menashi9,10, Juan Fernandez-Recio4, Samia Mourah1,2,3
1INSERM UMR-S 976, Hôpital Saint-Louis, Paris, France
2Université Paris-Diderot, Sorbonne Paris Cité, Paris, France
3Assistance Publique-Hôpitaux de Paris, Laboratoire de Pharmacologie-Génétique, Hôpital Saint-Louis, Paris, France
4Joint BSC-IRB Research Program in Computational Biology, Life Sciences Department, Barcelona Supercomputing Center, Barcelona, Spain
5Département de Neurosciences, Institut Pasteur, Unité de Neurobiologie Intégrative des Systèmes Cholinergiques, Paris, France
6Plateforme d'Imagerie, IUH, Hôpital Saint-Louis, Paris, France
7INSERM U728, Laboratoire de Pathologie, Hôpital Saint-Louis, AP-HP, Paris, France
8Département de Dermatologie Hôpital Saint Louis, Paris, France
9CNRS-UMR 7149, Laboratoire CRRET, Créteil, France
10Université Paris 12, Créteil, France
Samia Mourah, e-mail: email@example.com
Keywords: VEGFR-2, EMMPRIN/CD147, interaction/activation, coreceptor
Received: July 21, 2014 Accepted: December 07, 2014 Published: March 23, 2015
EMMPRIN/CD147 is mainly known for its protease inducing function but a role in promoting tumor angiogenesis has also been demonstrated. This study provides evidence that EMMPRIN is a new coreceptor for the VEGFR-2 tyrosine kinase receptor in both endothelial and tumor cells, as it directly interacts with it and regulates its activation by its VEGF ligand, signalling and functional consequences both in vitro and in vivo. Computational docking analyses and mutagenesis studies identified a molecular binding site in the extracellular domain of EMMPRIN located close to the cell membrane and containing the amino acids 195/199. EMMPRIN is overexpressed in cancer and hence is able to further potentiate VEGFR-2 activation, suggesting that a combinatory therapy of an antiangiogenic drug together with an inhibitor of EMMPRIN/VEGFR-2 interaction may have a greater impact on inhibiting angiogenesis and malignancy.
Primary Contact _
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.